• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    heart valve prosthesis. The present invention relates to a heart valve prosthesis, comprising a support structure in the form of a ring (3) to be fixed to the valve ring, and a valve leaflet (5) supported by the support structure. the support structure comprises a support wall portion (31) to which a root end 51) of the valve leaflet is connected, and a complementary wall portion (32) opposite the support wall portion, which supports a coaptation surface (33) adapted to be sealingly engaged by a free end (52) of the valve leaflet (5), and extending in a direction parallel to the direction of movement of the free end (32) of the valve leaflet (5) on the coaptation surface (33). the free end of the valve leaflet (5) is connected to the supporting wall portion or the complementary wall portion by means of a pulling member (55), dimensioned such that the free end (52) of the valve leaflet (5) is detained on the coaptation surface.
    公开号:BR112014026724B1
    申请号:R112014026724-3
    申请日:2013-04-26
    公开日:2021-06-01
    发明作者:Marcio Scorsin；Enrico Pasquino
    申请人:Epygon；
    IPC主号:
    专利说明:

    [0001] The present invention relates to a cardiac valve prosthesis comprising a support structure in the form of a ring to be attached to the valve ring, and a valve leaflet of flexible material floating supported by said support structure.
    [0002] In the mitral valve, the anterior leaflet of the valve covers the space between the valve commissures (including the trigones) and is in direct fibrous continuity with the aortic ring, including the fibrous trigone between the left and non-coronary aortic valve cusps . Thin bundles of collagen fibers that resemble tendons extend circumferentially from each fibrous trigone a variable distance toward the corresponding side of the mitral orifice. The posterior half to two-thirds of the ring that supports the posterior leaflet is mostly muscular, with little or no fibrous tissue. This muscle is mainly positioned perpendicular to the ring, and a less noticeable group of muscle fibers is located parallel to the ring.
    [0003] The mitral annulus corresponds to the transition between the endocardial layer of the left atrium, the valve tissue and the endocardium and myocardium of the left ventricle.
    [0004] The area of the mitral valve orifice in the annulus is approximately 6.5 cm2 in women and 8 cm2 in men. The circumference is approximately 9 cm in women and 10 cm in men. Depending on the inotropic state of the heart, the difference between diastolic and systolic ring size varies from 23% to 40%. The effective area of the valve orifice is approximately 30% smaller than the ring size.
    [0005] Although solutions for percutaneous transcatheter implantation of artificial aortic valves have been proposed, the distinctive features of the mitral valve have so far prevented the development of equally effective mitral valve prostheses.
    [0006] The following considerations have to be taken into account when designing a device to replace the mitral valve: • Degenerative disease: mitral valve prolapse is the most common pathological condition found in heart valves, and is present in approximately 2% of the population; 5% of these develop mitral regurgitation. Mitral prolapse is a degenerative condition in which calcification of the ring is found in rare cases. This is one of the main differences between aortic and mitral pathologies, as the mitral annulus is larger and more elastic, and these two characteristics make it difficult to fix a percutaneous device. • Mitral valve shape: the annulus and valve are asymmetric, with a long axis of about 5 cm between the commissures and a short axis of 4 cm in the anteroposterior direction in systole (usually with a long axis-to-axis relationship short from 4/4 to 3/4), when the valve is closed, because of the D-shape of the valve. During diastole, the ring moves outward with the posterior wall of the left ventricle, allowing the mitral orifice to become more circular. When pathological degenerative ring dilatation is present, the shape of the ring will become more circular throughout the cardiac cycle, primarily as a result of an increase in the posterior portion of the ring. This results in a change in mitral annulus diameters. The short axis (anteroposterior diameter) is elongated, making the shape of the valve more circular, thus preventing the perfect coaptation of the two leaflets and aggravating the mitral insufficiency. Although commercially available mitral prostheses are circular, in a percutaneous device, this can give rise to problems of coaptation (intraprosthetic insufficiency) and/or perivalvular escape. • Left ventricular pressure: when the left ventricle contracts, intraventricular pressure will force the mitral valve to close, the valve being subjected to the effects of systolic pressure. Systolic pressure is significantly higher than diastolic pressure (aortic valve); therefore, it is important to have perfect coaptation in a device intended for mitral position. • Left ventricular tract obstruction: when the mitral valve is surgically replaced, the anterior leaflet will be completely excised. One of the main issues related to a percutaneous implant of a mitral valve prosthesis is that the anterior leaflet cannot be removed. The retaining leaflet may result in a potential obstruction of the left ventricular tract when pressed into the ventricle by the prosthesis. The larger the size of the valve prosthesis, the greater the risk of obstruction as the leaflet is pressed further into the ventricle. • Patients with mitral rings (anuloplasty): patients who have had a mitral repair operation may develop recurrent regurgitation. Circular artificial aortic valves do not operate correctly in patients with D-shaped mitral rings, as they do not allow for perfect coaptation of the three leaflets; in addition, due to the deformation of the structure, perivalvular escape occurs due to the lack of coupling between the circular shape and the D shape, as well as a reduced stability of the implant with a risk of prosthesis migration.
    [0007] For the above reasons, there are major limitations on the use, for example, of percutaneous or sutured aortic valve implant systems in the mitral position. Valve replacement percutaneously or by minimally invasive surgery is becoming an increasingly common practice for aortic and pulmonary valves, although it has so far not been used for mitral valve.
    [0008] As explained above, the mitral annulus differs from the aortic annulus in that it is not circular, especially in a patient with a mitral annuloplasty ring. Available transcatheter prostheses are always tricuspid, and if they are not perfectly circular after expansion (due to irregular stent expansion), they will tend to reduce the degree of coaptation of the valve leaflets, resulting in prosthetic insufficiency. Since the aortic annulus is practically circular, transcatheter valves almost always work well unless the stent is distorted during implantation due to the presence of dystrophic calcification of the annulus and valve leaflets. The risk of insufficiency in the mitral position, which is not circular, is very considerable, since the mitral annulus does not offer any resistance during the expansion of the prosthesis, thus leading to overdilation and consequent loss of coaptation between the three valve leaflets.
    [0009] An objective of the present invention is to provide a heart valve prosthesis that can at least partially overcome the problems of the prior art described above.
    [00010] The above-mentioned objective is achieved according to the invention with a heart valve prosthesis of the initially defined type, where said support structure comprises a supporting wall portion to which a leaflet root end is connected. valve leaflet, and a complementary wall portion opposite said support wall portion, which supports a static or quasi-static coaptation surface adapted to be sealingly engaged by a free end of the valve leaflet, and extending in a substantially parallel direction the direction of movement of the free end of the valve leaflet on the coaptation surface; said free end of the valve leaflet being connected to said supporting wall portion or to said complementary wall portion preferably at its side portions by means of at least one flexible material pulling member, dimensioned in such length as the movement the end of the valve leaflet is interrupted at said coaptation surface. The invention was developed based on examination of the prior art in the field of heart valve repair.
    [00011] As explained by Carpentier, the goal of mitral valve repair is to restore a good coaptation surface in order to provide a satisfactory mitral valve function (Carpentier A. Cardiac valve surgery - the "French correction."J Thorac Cardiovasc Surg 1983;86:323-37). Conventionally, the repair of a posterior valve leaflet prolapse consists of leaflet resection followed by annuloplasty using a ring, and this has been shown to have excellent long-term durability. Typically, echocardiographic findings after mitral valve repair show a posterior leaflet with reduced mobility or no mobility at all, which hangs vertically from the ring and shape, as experimentally and clinically demonstrated (Cohn, LH, Couper, GS, Aranki, SF , et al. Long-term results of mitral valve reconstruction for regurgitation of the myxomatous mitral valve J Thorac Cardiovasc Surg 1994; 107: 143-51), a support against which the anterior leaflet rests in apposition. These conclusions were further developed by Perier (Perier, P., Hohenberger, W., Lakew, F., Batz, G., Urbanski, P., Zacher, M., and Diegeler, A. Toward a new paradigm for The reconstruction of the posterior leaflet prolapse: midterm results of the "respect rather than resect" approach. Ann Thorac Surg 2008 Sep; 86(3): 718-25), which deliberately converted the bicuspid mitral valve into a monocuspid valve by apposition of the anterior leaflet on an extended coaptation surface formed on the verticalized posterior leaflet.
    [00012] The concept on which the invention is based, therefore, is that of the coaptation of a single extended leaflet on a wall that supports an extended, smooth, regular and substantially vertical coaptation surface, thus reducing the risk of involuntary regurgitation. traprosthetics. Additionally, the leaflet edge is held by a traction member that simulates a tendon chord system.
    [00013] Due to the fact that only one leaflet is present, a larger mobile surface is subjected to the pressures created by the cardiac cycle. This results in faster opening and closing of the valve compared to tricuspid valves. Additionally, the use of a monocuspid valve could reduce the incidence of calcification phenomena. It is certainly known that, in some tricuspid-type devices, fibrosis of the valve leaflets sometimes occurs with the formation of intrinsic and extrinsic dystrophic calcification in the less mobile part of the leaflet. From this, it can be deduced that the continuous movement of the single leaflet could contribute to the prevention of fibrosis and tissue calcification (Gabbay, S., Bortolotti, U., Cipoletti, G., Wasserman, F., Frater, RW, and Factor, SM The Meadox unicusp pericardial bioprosthetic heart valve: new concept Ann Thorac Surg 1984 Jun; 37(6); 448-56).
    [00014] The support structure preferably has a D-shaped cross section in a plane perpendicular to the axis of the structure, that is, the axis corresponding to the direction of blood flow, when the support structure is implanted.
    [00015] Shape D, as used herein, is any shape that comprises two parts, one of which is bent approximately circularly, while the other part is substantially straight or bent to a small degree on each side, respectively.
    [00016] The straight part could also be bent slightly after implantation. With the folding of the straight part "in vivo", the native leaflet can be pulled upwards with respect to the blood flow. In addition, the portion shows better fastening conditions after folding.
    [00017] The substantially straight part is preferably the supporting wall portion and the bent part is preferably the complementary wall portion comprising the coaptation surface.
    [00018] Alternatively, the straight part is the complementary wall portion comprising the coaptation surface and the folded part is the supporting wall portion.
    [00019] The cross section of the mitral valve ring has a D shape. A support structure with a D shape therefore provides a better fit between the ring and the support structure, as there is contact between the ring and the structure of support substantially around the support structure. A better fit and a better contact between the support structure and the ring result, for example, in better stability of the implant, as well as a reduced risk of perivalvular escape. Furthermore, the aortic annulus is not compressed as a result of a mitral prosthesis implant, as there is no expansion of the mitral annulus with a D-shaped support structure, especially no expansion of the mitral annulus towards the aortic annulus, therefore , on the front side.
    [00020] The anterior side of the support structure is the side that is disposed close to the aortic ring when deployed. The front side is preferably the complementary wall portion. The posterior side is opposite the anterior side and therefore at maximum distance from the aortic ring when implanted. The back side is preferably the supporting wall portion.
    [00021] The dimensions of the support structure are preferably such that a distance perpendicular to the anteroposterior distance is preferably from about a factor of 1.1 to 1.3, but preferably from about a factor of 1.2, more longer than the anteroposterior distance. The axial length of the support structure is preferably about 32 mm and the wall thickness as well as the width of the supports is preferably about 500 µm (micrometers).
    [00022] In a preferred variation, the inflow end and the outflow end are flared outward with respect to the flow direction and the cardiac wall. The inflow end is preferably widened by about 20° to 40°, more preferably by about 30°, with respect to the flow direction and the outflow end is preferably widened by about 7.5° to 17.5° , more preferably about 10° with respect to the flow direction.
    [00023] In an alternative modality, the ends of the prosthesis are asymmetrically widened in such a way that the anterior side presents a different enlargement than the posterior side. The front side in the range is preferably widened at the outflow end preferably by about 7.5° to 17.5°, more preferably by about 10° with respect to the axis and widened at the inflow end preferably by about 15° at 25°, but preferably by about 20°, with respect to the axis, while the rear side is flared at the outflow end, preferably by about 7.5° to 17.5°, more preferably by about 10 ° with respect to the axis and at the inflow end at about 20° to 40°, but preferably at about 30° with respect to the axis. Asymmetric widening could be present in combination with the various prostheses of the invention described herein.
    [00024] In an alternative modality, the flares could be provided as curvilinear flares. Curvilinear flares indicate that the flares are bent in a kind of circular convex way with respect to the axis, so that the flare bends outward first and at least slightly inward towards the inflow end or the outflow end, respectively , with respect to the axis. Curvilinear flares could be present in combination with the various prostheses of the invention described herein.
    [00025] The flares provide a strength of the support structure at the atrioventricular junction and surrounding tissues of the posterior ventricular wall that maintain the fixation of the support structure in the ring. A smaller flare at the outflow end of the anterior portion than at the posterior portion helps to minimize the risk of obstruction of the left outflow tract.
    [00026] In another variation of the prosthesis, the support structure has an asymmetrical arrangement in the axial direction, such that one side, preferably the anterior side, is shorter than an opposite side in the axial direction, preferably the posterior side.
    [00027] The asymmetrical arrangement is preferably constructed in such a way that the anterior portion is so short that the native leaflet is not basically pressed out into the left ventricle. In the left ventricle, the native leaflet could interfere with the efflux of blood through the aorta in systole.
    [00028] Native leaflets will not be excised when performing a procedure without CPB (extracorporeal circulation). Native leaflets are somewhat pressed to the side, therefore out of the opening, with the prosthesis in such a way as not to interfere with blood flow. However, with an anterior portion of a certain length, the anterior native leaflet could be pressed into the left ventricle. When the heart contracts during systole to press blood out of the aorta, the anterior native leaflet could block some of the blood flow through the aorta when covering some parts of the aortic ring. With a shorter anterior portion, the anterior leaflet is not pressed into the left ventricular tract but moves into the inflow tract.
    [00029] The asymmetric construction could be part of any prosthesis discussed here.
    [00030] It is also possible that the front and back portions have the same length.
    [00031] In any prosthesis, the valve and at least one traction member could be constructed as a single piece, preferably as a single piece formed from the pericardium.
    [00032] The traction limb and valve could be excised from the pericardium as one piece. With a one-piece construction, there is no need to connect the traction member to the valve leaflets. A construction without a connection is more stable than a two-piece construction. Therefore, the risk of a malfunction is reduced.
    [00033] It is also possible to construct the drive member and valve as two or more piece arrangements.
    [00034] The pericardium has been shown to be persistent and therefore well suited for purposes such as valve and traction limb. It is also possible to use other biocompatible materials, such as biocompatible plastics or fabrics.
    [00035] At least one traction member is preferably connected to the lateral portions of the support structure.
    [00036] The side portions are the two sides of the support structure that include the rear ends of the front side and the rear side. The front side and the back side preferably refer to the complementary wall portion and the supporting wall portion. The connection of the pulling member can be anywhere along the side portions.
    [00037] When the traction members are arranged in the lateral portions, their interference with the valve movement will be minimized as the valve leaflet preferably opens in an anteroposterior direction.
    [00038] The invention further comprises a dispensing device comprising a prosthesis according to the invention described herein.
    [00039] Additionally, the invention relates to a method for manufacturing a heart valve prosthesis, preferably a prosthesis according to the invention described herein, comprising the steps of: - providing a support structure, preferably a support structure of shape D with a support wall portion and a complementary wall portion, - mount a flexible material valve leaflet on the support structure, where the valve leaflet is connected with a root end to the support wall or the wall complementary, preferably by suturing, and a free end of the valve is connected to the other wall portion, the complementary wall portion or the supporting wall portion, through a traction member.
    [00040] In the manufacturing method, the valve and the pulling member are preferably constructed as a single piece. Although the characteristics and advantages of the prosthesis according to the invention are discussed here in relation to mitral valve replacement, it will be clear that the concept of the invention can also be applied to valve prostheses intended for the replacement of other heart valves.
    [00041] Additional features and advantages of the prosthesis according to the invention will be evident from the following detailed description, which refers to the attached drawings, provided purely by way of non-limiting example, in which: Figure 1a shows a perspective view simplified from above a valve prosthesis according to the invention; Figure 1b shows a simplified schematic view in cross section (A2-P2 according to Carpentier) of a valve prosthesis according to the invention; Figure 2 is a perspective view from below (showing the outflow side) of the valve prosthesis of Figure 1a; for clarity, part of the prosthesis is shown as transparent; Figure 3 is a plan view (showing the inflow side) of the valve prosthesis of Figure 1a; Figure 4 is a sectional view of the valve prosthesis taken along line IV-IV in Figure 3; Figures 5 to 7 are perspective views from below of different modalities of the valve prosthesis; Figure 8 is a plan view of an additional valve prosthesis; Figure 9 is a sectional view of the valve prosthesis taken along line IX-IX in Figure 8; Figure 10a is a perspective view from below (showing the outflow side) of the valve prosthesis in the closed position; Figure 10b is a perspective view from below (showing the outflow side) of the valve prosthesis in the open position; Figure 11a is a side view of the valve prosthesis; Figure 11b is a top view (inflow view) of the valve prosthesis.
    [00042] With reference to Figures 1 to 4, a heart valve prosthesis according to the invention, shown schematically, is indicated as a whole by 1. This prosthesis 1 comprises a support structure in the form of a ring 3 to be fixed in the valve ring, which may have already been repaired with an annuloplasty ring. With respect to the direction perpendicular to the cross-section of the ring, the support structure 3 has an inflow side or end 3b and an outflow side or end 3a. In this context, the terms "inflow" and "outflow" refer to the inflow and outflow of blood to and from the valve, when using the prosthesis.
    [00043] In flat view (Figure 3), the illustrated valve has a D shape, making it suitable for implants in the atrioventricular position (mitral or tricuspid). In an alternative embodiment which is not shown, the valve according to the invention may have a circular shape suitable for implants in the aortic or pulmonary position.
    [00044] Preferably, as schematically shown in Figure 1b, the support structure 3 comprises a 3' skeleton formed by a valve stent, which can assume a positioning configuration in which the stent is folded to allow it to be positioned across a catheter, and an implant configuration in which the stent is expanded to be fitted and secured to the valve ring. In order to achieve this expansion in position, the stent material may be a self-expanding material, for example a shape memory alloy, or a formed balloon associated with the positioning system may be provided, this balloon being inflated. to produce stent expansion. The aforementioned expansion may also provide a change in the shape of the prosthesis, particularly in order to create the D-shape of the mitral or tricuspid valve.
    [00045] More specifically, the prosthesis according to the positioning system can be transferred to the implant site by a surgical procedure without CPB suture (extracorporeal circulation), by a surgical procedure without CPB (extracorporeal circulation) with transatrial or transapical access through a minithoracotomy, or, last but not least, through an intervention procedure with percutaneous access.
    [00046] The loosening of the prosthesis from the positioning system can happen in a single action or it can be a two-step procedure. In a first step, a portion of the prosthesis (either the inflow portion or the outflow portion, depending on the implant method and visualization procedure) is released so that its vertical and horizontal positioning can be adjusted. In the second step, the second portion of the prosthesis is released (complete release).
    [00047] Preferably, the valve prosthesis is of the sutureless type, that is, no suture is needed to secure it to the valve seat. For this purpose, the support structure 3 can be anatomically formed so as to be firmly fixed to the valve ring, or it can be provided with purpose-built formations for fixation.
    [00048] More specifically, the outer portion of the valve stent that comes in direct contact with the native fibrous valve annulus may be slightly concave in order to follow the contour of the annulus and facilitate fixation on it. The valve stent structure in this area may also include fixations formed by grafts integrated into the structure itself. Other possibilities to support the fixation are hooks or brackets. This method of fixation prevents the progressive dilation of the fibrous ring, thus reducing the risk of perivalvular leakage and disconnection of the prosthesis. Fixation occurs together with the opening of the atrial and ventricular portions of the valve stent.
    [00049] Preferably, the atrial (inflow) portion of the valve stent has a special retractable mesh design like the rest of the stent, and, at the end of the prosthesis opening, assumes an outwardly flared shape such that the secure contact can be established with the atrial wall (inflow). The purpose of this portion of the prosthesis is to ensure the positioning of the prosthesis through progressive colonization by fibrous tissue (fibrous pannus). The profile of the atrial portion (inflow) is higher in the posterior anatomical portion and lower in the anterior portion, the objective being, in the latter case, to reduce any possible interference with the aortic valve. This structure can be formed from metal alloy only, or can be covered with biological or synthetic tissue in order to optimize colonization by fibrous tissue.
    [00050] Preferably, the ventricular portion (outflow) of the valve stent has a special retractable mesh design like that of the atrial portion (outflow). The profile is remarkably asymmetric. The posterior ventricular portion (outflow) has a marked bulge, which not only provides contact with the posterior ventricular wall (outflow), but also provides a limb for attachment to the support (cords) of the anterior monocuspid valve leaflet and to the cords of any leaflet later as described below. It can take the form of a single structure or two or three separate structures. The anterior ventricular part (outflow) presents a low profile and acquires an enlarged shape to promote the fixation of the prosthesis to the ventricle without interfering with the mitral-aortic continuity, in order to prevent the creation of compression that would lead to conduction disturbances. The anterior ventricular side of the stent in its most distal portion could have a turned angle close to 180°. Therefore, the stent could originally have a symmetric D-shape and, after thermal modeling, only the anterior ventricular part could be overturned, making it asymmetric. This condition could involve grasping the edge of the native anterior leaflet and the native leaflet toward the atrium, leaving the left ventricular tract free. Furthermore, the fixation of the anterior ventricular portion is improved with a twisted ventricular portion. The ventricular (outflow) portion of the stent can be made of metal alloy only, or it can be covered with biological or synthetic tissue in order to optimize colonization by fibrous tissue.
    [00051] As a rule, the support structure 3 of the valve prosthesis can have a 3'' coating, of pericardium, for example, or of biological tissue, in general, or of synthetic tissue, covering part or all of the structure of Support. The 3'' coating will be particularly needed if the support structure is a 3' valve stent, in order to provide a seal in the valve ring in which the prosthesis is fitted.
    [00052] The valve prosthesis additionally comprises a single valve leaflet 5 of flexible material buoyantly supported by the support structure 3. The flexible material of the valve leaflet has to have characteristics that satisfy the requirements of resistance to cyclic fatigue. The valve leaflet 5 can be formed from pericardial tissue, or biological tissue, in general, or synthetic tissue. The pericardial tissue, in addition to conventional reticulated tissue fixation, should preferably be subjected to chemical treatment that serves to provide a long-term delay in dystrophic calcification of the biological tissue. The valve leaflet can be formed as an extension type of the material covering the support structure 3 of the prosthesis, or as a separately produced part which is subsequently fixed to the support wall portion 31 of the support structure 3. In one view flat (Figure 3), the surface extension of the valve leaflet 5 in the example of Figures 1 to 4 is substantially equal to the cross section of the hole delimited by the support structure 3.
    [00053] In relation to this valve leaflet, the support structure 3 comprises a support wall portion 31 to which a root end 51 of the valve leaflet 3 is connected. For this purpose, the efflux portion 3b of the stent Valve features a valve support for the valve leaflet of the prosthesis. This support is integrated into the stent structure, and is designed to withstand cyclic fatigue stress, to provide adequate support for the valve leaflet, and to allow the prosthesis to be completely ruptured for insertion into the positioning system.
    [00054] The support structure 3 further comprises a complementary wall portion 32 connected and opposite the support wall portion 31, which supports a coaptation surface 33 (visible in Figures 1b and 4) adapted to be sealingly engaged by one end free 52 of the valve leaflet 5. In the example shown in Figures 1 to 4, the coaptation surface 33 is static in the sense that it is integral with the supporting structure 3 of the valve prosthesis. In particular, in the example of Figures 1 to 4, the coaptation surface 33 is defined by an inner face (i.e. a face facing the center of the valve prosthesis) of the complementary wall portion 32 of the support structure 3. On the coaptation surface, the complementary wall portion 32 of the support structure 3 has the coating discussed above.
    [00055] If the valve prosthesis in question is a mitral prosthesis, the supporting wall portion 31 of the supporting structure 3 will be an anterior wall portion of this supporting structure, while the complementary wall portion 32 will be a portion of back wall. The terms "anterior" and "superior" refer to the positioning of the valve prosthesis in use in the mitral annulus.
    [00056] In use, the valve leaflet 5, which is flexible and connected to the support structure 3 by its root end 51, is capable of being bent with respect to its root end 51, under the action of blood pressure at upstream and downstream of the valve prosthesis, thus opening or closing the hole formed by the supporting structure 3 of the valve prosthesis. In the closed position, the edge of the free end 52 of the valve leaflet 5 engages the coaptation surface 33 positioned on the complementary wall portion 32 of the support structure 3.
    [00057] The coaptation surface 33 extends in a direction substantially parallel to the direction of movement of the free end 52 of the valve leaflet 5 on the coaptation surface 33. When the valve prosthesis is in use, the aforementioned direction will be substantially vertical . In this way, it is possible to obtain a large coaptation surface, similar to that obtained with the Perier method to create a mitral annuloplasty; the coaptation surface may have an extension h (see Figure 1b) of at least 5 mm in the direction of movement of the free end 52 of the valve leaflet. Consequently, the possibility of regurgitation will be reduced if the prosthesis is deformed.
    [00058] As can be seen in Figures 2 and 3, the free end 52 of the valve leaflet 5 is connected to the supporting wall portion 31 by at least one traction member 55 of flexible material (in the present example, two are provided. of these members). The traction members 55 simulate the retaining/interrupting function of the natural tendinous chords, and are therefore dimensioned to such a length that the movement of the free end 52 of the valve leaflet 5 is interrupted at the coaptation surface 33.
    [00059] The traction members 55 may be formed of the same material as the valve leaflets 5 or of a different material, and may be formed to resemble extensions of the free end 52 of the leaflet, or as separately formed elements that are subsequently fixed to the free end of the valve leaflet.
    [00060] The other ends of the traction members 55 are fixed to the support structure 3 on the side (blood inflow side 3a) axially opposite to the side (blood outflow side 3b) on which the valve leaflet is positioned. In order to connect the traction members to the support structure 3 and support them thereon, it is possible to provide post-portions 35 which project axially from the support structure 3 on the inflow side 3a of the valve prosthesis.
    [00061] Preferably, predetermined areas (for example, areas adjacent to the commissural region) of the support structure 3 are provided with markers formed from material opaque to radiation of predetermined wavelength, for example, a radiopaque material such as a metal noble, for example platinum or tantalum. The markers serve to facilitate the implantation of the prosthesis during a procedure that uses fluoroscopy, by providing a spatial reference for the operator, which must be aligned with an anatomical reference.
    [00062] Figure 5 shows another exemplary modality of a valve prosthesis according to the invention. Elements corresponding to those of the previous modality received the same reference numerals; for a detailed explanation of these elements, reference should be made to the preceding part of the description.
    [00063] The prosthesis of Figure 5 differs from that of Figures 1 to 4 in that it has only one traction member 55 instead of a pair of traction members 55. Consequently, the prosthesis of Figure 5 has a single post-portion 35, to which the end of the pulling member 55 is connected.
    [00064] More generally, the number of traction members 55 may vary according to circumstances; in an embodiment which is not illustrated, a plurality of traction members of different lengths are provided, connected to a plurality of points distributed along the edge of the free end 52 of the valve leaflet 5. This arrangement allows for the stresses acting on the 5 valve leaflet are evenly distributed. In a further embodiment which is not illustrated, a single traction member is provided which forms an integral extension of the valve leaflet 5, and which therefore extends along the entire edge of the free end 52 of the valve leaflet 5. This configuration allows the stress distribution to be further improved.
    [00065] Figure 6 shows a third exemplary modality of a valve prosthesis according to the invention. Elements corresponding to those of the previous modalities received the same reference numerals; for a detailed explanation of these elements, reference should be made to the preceding part of the description.
    [00066] The prosthesis of Figure 6 differs from that of Figure 5 in that the traction member 55 is connected to the complementary wall portion 32, than to the supporting wall portion, in a position that is therefore diametrically opposite to that shown in Figure 5. Consequently, the prosthesis of Figure 6 has a post-portion 35 positioned on the complementary wall portion 32, to which the end of the traction member 55 is connected.
    [00067] Figure 7 shows a further exemplary embodiment of a valve prosthesis according to the invention. Elements corresponding to those of the preceding modalities received the same reference numerals; for a detailed explanation of these elements, reference should be made to the preceding part of the description.
    [00068] The prosthesis of Figure 7 differs from that of Figure 6 in that it has traction members 55 instead of a single traction member 55. Consequently, the prosthesis of Figure 7 has three support portions 35, to which they are respectively connected the ends of the traction members 55.
    [00069] In a variant of the invention shown in Figures 8 and 9, the coaptation surface 33 is formed by an almost static coaptation leaflet 6, positioned on the complementary wall 32 of the support structure 3. For the purposes of the present invention, the term "almost static" indicates that the coaptation leaflet 6 has reduced mobility compared to the valve leaflet 3. The coaptation leaflet 6 comprises a root end 62 connected to the complementary wall portion 32 of the support structure 3. For this purpose, the 3a efflux portion of the valve stent provides a valve support for the coaptation leaflet of the prosthesis. This support is integrated into the stent structure, and is designed to withstand cyclic fatigue stress, to provide adequate support for the coaptation leaflet, and to allow the prosthesis to be completely ruptured for insertion into the positioning system.
    [00070] The coaptation leaflet 6 further comprises a free end 61 connected to the complementary wall portion 32 by means of at least one traction member 65 of flexible material, dimensioned to such a length that the coaptation leaflet 6 is kept folded in the direction of the complementary wall portion 32. In order to connect the traction member 65 to the support structure 3 and support it therein, it is possible to provide post-portions that project axially from the support structure 3 on the inflow side of the prosthesis. valve. The number and extent of the traction members 65 of the coaptation leaflets may vary in a manner similar to that described above with respect to the traction members 55 of the valve leaflet 5. In the variation, the traction member 65 is arranged in such a way. that the free end 61 is aimed at an outflow end 3a. The materials from which coaptation leaflet 6 is made are the same as those from which valve leaflet 5 is formed.
    [00071] As can be seen in Figure 8, the surface extension of the valve leaflet 5 is significantly greater than that of the coaptation leaflet 6. The attachment line of the coaptation leaflet on the wall of the valve stent ends in continuity with the line of fixation of the valve leaflet 5, forming two commissures in the anteroposterior position. The length of the attachment line for the anterior leaflet (5) is typically about 40% of the annular circumference, while the posterior leaflet (6) is the remaining 60%. The depth of the commissure must be at least 5 to 8 mm, similar to that of the rest of the coaptation surface 33.
    [00072] As a rule, the valve leaflet, and the coaptation leaflet, if present, will preferably be fixed directly to the valve stent in the inflow and in the postportions (in the outflow) by the interposition of biological or synthetic tissue. By means of this system, the leaflet elongation shock during the systole/diastolic phases can be absorbed together on the coaptation surface in the two leaflets, thus increasing the durability of the prosthesis over time.
    [00073] Figure 10a shows a perspective view of the support structure 3 of the outflow end 3a in a closed position. The closed position indicates that the valve leaflet 5 prevents backflow of blood through the support structure 3. The valve leaflet 5 and the two traction members 55 are formed as a single formed piece of pericardium. Leaflet 55 is sutured to support wall portion 31 along sutures schematically shown. The free end 52 of the valve leaflet 5 is in contact with the complementary wall portion 32 in the closed position. Traction members 55 are sewn to the side portions 34 of the support structure 3 along sutures schematically shown. The traction members 55 prevent further movement of the valve leaflet 5 in the closed position, thus ensuring a sealed closure.
    [00074] Figure 10b shows a perspective view of the support structure 3 of the outflow end 3a in an open position. The open position indicates that the valve leaflet 5 does not basically interfere with blood flow through the support structure 3 from the left atrium to the left ventricle during diastole. The free end 52 of the valve leaflet 5 is at a distance with respect to the complementary wall portion 32. Two traction members 55 are attracted to the side portions 34 and the free end 52 of the valve leaflet 5.
    [00075] Figure 11a shows a wide view of the support structure 3 with the valve leaflet 5 mounted inside the support structure 3. The valve leaflet 5 is sewn to the side portions 34 by means of the traction members 55 to the along the sutures schematically shown. Inflow end 3b has a 10° flare with respect to the blood flow direction. The 3a outflow end has a 30° widening with respect to the direction of blood flow. The axial length d1 of the inflow end 3b is shorter than the shorter axial length d2 of the outflow end 3a. The outflow end flare 3a is arranged in a curvilinear fashion. There is an outwardly flared portion 61 and a slightly inwardly bent portion 60 with respect to the direction of blood flow. The flares could also be present in a more curvilinear fashion. Furthermore, the flares are asymmetrically arranged. The anterior portion corresponding to the supporting wall portion 31 is widened at an angle α1. α1 is smaller than the angle α2 present in the widening of the posterior portion corresponding to the complementary wall portion 32.
    [00076] The support structure comprises multiple supports that form cells. The supports are 500 µm wide. A wall thickness of the support structure 3 is also 500 µm. The support structure has an axial length D of about 32 mm from the inflow end 3b to the outflow end 3a measured in the support wall portion 31. The cells in the outflow end 3a may have a larger dimension than the cells at the inflow end 3b. A front portion corresponding to support wall portion 31 in Figure 11a is shorter in the axial direction than a rear portion corresponding to complementary wall portion 32. Side portions 34 connect the front portion and the rear portion such that the lateral portions benefit from the constant length from the anterior portion to the posterior portion. The support structure could be formed from Nitinol.
    [00077] Figure 11b shows a top view of the support structure 3 that houses the valve leaflet 5. The support structure is presented in a D shape. The D shape is arranged in such a way that the anterior portion corresponding to the portion of support wall 31 in Figure 11b is only slightly convexly bent and the rear portion corresponding to the complementary wall portion 32 is convexly bent with a smaller radius of curvature. The distance between the lateral portions 34 is 1.2 times as great as the distance between the anterior portion and the posterior portion.
    权利要求:
    Claims (20)
    [0001]
    1. Heart valve prosthesis comprising a support structure in the form of a ring (3) to be fixed to the valve ring, and a valve leaflet (5) of flexible material buoyantly supported by said support structure, characterized in that the said support structure comprises a support wall portion (31) to which a root end (51) of the valve leaflet is connected, and a complementary wall portion (32) opposite said support wall portion, which supports a static or quasi-static coaptation surface (33) adapted to be sealingly engaged by a free end (52) of the valve leaflet (5), and extending in a direction substantially parallel to the direction of movement of the free end (52) of the valve leaflet (5) on the coaptation surface (33); said free end of the valve leaflet (5) is connected to said support wall portion (31) or to said complementary wall portion (32) by means of at least one traction member (55) of flexible material, which is dimensioned in such length that the movement of the free end (52) of the valve leaflet (5) is interrupted on said coaptation surface (33) where the support structure (3) has a cross section in the shape of D, the straight part of the form D being the supporting wall portion (31) and the bent part of the form D being the complementary wall portion (32).
    [0002]
    2. Prosthesis according to claim 1, characterized in that said coaptation surface (33) extends in the direction parallel to the direction of movement of the free end (52) of the valve leaflet (5) by a width (h ) of at least 5 mm.
    [0003]
    3. Prosthesis, according to claim 1 or 2, characterized in that said coaptation surface (33) is formed by an inner face of said complementary wall portion (32) of the support structure (3).
    [0004]
    4. Prosthesis according to claim 1 or 2, characterized in that said coaptation surface (33) is formed by a quasi-static coaptation leaflet (6) comprising a root end (61) connected to said portion of complementary wall (32), and a free end (62) connected to said support wall portion (31) or to said complementary wall portion (32) by means of at least one tension member (65) of flexible material. , which is dimensioned to such a length that said coaptation leaflet (6) is held towards said complementary wall portion (32).
    [0005]
    5. Prosthesis, according to any one of the preceding claims, characterized in that said support structure (3) comprises a skeleton consisting of a valve stent, which is capable of assuming a dispense configuration where the stent is ruptured, and an implant configuration where the stent is expanded.
    [0006]
    6. Prosthesis, according to any one of the preceding claims, characterized in that said support structure (3) is configured for an implant without suture in the valve ring.
    [0007]
    7. Prosthesis according to any one of the preceding claims, characterized in that at least one said traction member (55) is connected to a post-portion (35) of said supporting wall portion (31) or said portion of complementary wall (32), said post-portion projecting axially from the blood outflow side (3a) of said support structure (3).
    [0008]
    8. Prosthesis, according to any one of the preceding claims, characterized in that at least a predetermined area of said support structure (3) is provided with a positioning marker of material opaque to radiation of a predetermined wavelength.
    [0009]
    9. Prosthesis, according to any one of the preceding claims, characterized in that a plurality of said traction members (55) having different lengths is provided which is connected to a plurality of locations distributed along the edge of the free end (52 ) of the valve leaflet (5).
    [0010]
    10. Prosthesis, according to any one of claims 1 to 8, characterized in that said traction member (55) constitutes an integral extension of the valve leaflet (5), and extends transversely along the entire edge of the free end (52) of the valve leaflet (5).
    [0011]
    11. Prosthesis, according to any one of the preceding claims, characterized in that the valve and at least one traction member (55) are constructed as a single piece, preferably as a single piece formed from pericardium.
    [0012]
    12. Prosthesis, according to any one of the preceding claims, characterized in that at least one traction member (55) is connected to the side portions (34) of the support structure.
    [0013]
    13. Prosthesis, according to any one of the preceding claims, characterized in that the ends of the support structure (3) are widened outwards with respect to a direction of blood flow.
    [0014]
    14. Prosthesis according to claim 13, characterized in that the flared ends are differently flared such that one end, preferably an inflow end, is flared at a wider angle with respect to the direction of blood flow than an opposite end, preferably an outflow end.
    [0015]
    15. Prosthesis having a support structure (3) and at least one valve leaflet (6) supported by said support structure (3), according to any one of the preceding claims, characterized in that a support structure (3 ) present an asymmetrical arrangement such that one side, preferably the front side, is axially shorter than an opposite side, preferably the back side.
    [0016]
    16. Prosthesis having a support structure (3) and at least one valve leaflet (5) supported by said support structure (3), according to any one of the preceding claims, characterized in that the ends of the support structure (3) be curvilinearly enlarged with respect to the direction of blood flow.
    [0017]
    17. Prosthesis having a support structure (3) and at least one valve leaflet (5) supported by said support structure (3), according to any one of the preceding claims, characterized in that the ends of the support structure (3) are asymmetrically widened such that one side, preferably an anterior side, is widened at a wider angle with respect to the direction of blood flow than an opposite side, preferably a posterior side.
    [0018]
    18. Dispensing device, characterized in that it comprises a prosthesis as defined in any one of claims 1 to 17.
    [0019]
    19. Method of manufacturing a heart valve prosthesis, preferably a prosthesis as defined in any one of claims 1 to 17, characterized in that it comprises the steps of: - providing a support structure (3), preferably a support structure D-shaped support with a support wall portion (31) and a complementary wall portion (32), - mount a flexible material valve leaflet on the support structure (3), where the valve leaflet is connected with a root end (51) to the support wall (31) or to the complementary wall (32), preferably by suture, and a free end (52) of the valve is connected to the other wall portion, the complementary wall portion ( 32) or the support wall portion (31) via a pulling member.
    [0020]
    20. Method according to claim 19, characterized in that the valve and the traction member (55) are constructed as a single piece, preferably a single piece formed from pericardium.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112014026724B1|2021-06-01|HEART VALVE PROSTHESIS, DISPENSE DEVICE AND METHOD OF MANUFACTURING A HEART VALVE PROSTHESIS
    US10869757B2|2020-12-22|Valve prosthesis and method for delivery
    US10070954B2|2018-09-11|Mitral heart valve replacement
    US10213302B2|2019-02-26|Valve prosthesis and method for delivery
    BR102015024747B1|2022-01-11|IMPLANTABLE DEVICE TO TREAT MITRAL VALVE REGURGITATION
    US8357195B2|2013-01-22|Catheter based annuloplasty system and method
    IL242502A|2020-10-29|Heart valve assistive prosthesis
    BRPI0911351B1|2019-12-31|stent structure for a prosthetic heart valve, and prosthetic heart valve
    CN111904664A|2020-11-10|Tricuspid valve prosthesis
    CN212382790U|2021-01-22|Heart valve device with anchoring ring
    同族专利:
    公开号 | 公开日
    EP2841019A1|2015-03-04|
    CA2870791C|2018-04-03|
    US10278814B2|2019-05-07|
    IN2014DN09196A|2015-07-10|
    CA2870791A1|2013-10-31|
    CN104394803B|2017-09-12|
    BR112014026724A2|2017-06-27|
    US20150088248A1|2015-03-26|
    JP6290860B2|2018-03-07|
    AU2013254678A1|2014-11-27|
    KR20150013611A|2015-02-05|
    MY175191A|2020-06-13|
    AU2013254678B2|2017-05-11|
    JP2015516217A|2015-06-11|
    IL235285D0|2014-12-31|
    SG11201406936PA|2014-11-27|
    KR101876959B1|2018-07-11|
    UA115241C2|2017-10-10|
    WO2013160439A1|2013-10-31|
    RU2631410C2|2017-09-21|
    MX2014012950A|2015-04-08|
    CN104394803A|2015-03-04|
    IL235285A|2019-10-31|
    RU2014145477A|2016-06-20|
    MX353430B|2018-01-12|
    ITTO20120372A1|2013-10-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2742681C3|1977-09-22|1980-07-31|Dr. Eduard Fresenius, Chemisch- Pharmazeutische Industrie Kg, 6380 Bad Homburg|Prosthetic closure element to replace the mitral and tricus pldal valve in the human heart|
    US4759758A|1984-12-07|1988-07-26|Shlomo Gabbay|Prosthetic heart valve|
    US4960424A|1988-06-30|1990-10-02|Grooters Ronald K|Method of replacing a defective atrio-ventricular valve with a total atrio-ventricular valve bioprosthesis|
    AU2346992A|1991-06-06|1993-01-08|Medtronic, Inc.|Composite curvature bileaflet prosthetic heart valve|
    US5713950A|1993-11-01|1998-02-03|Cox; James L.|Method of replacing heart valves using flexible tubes|
    US20050070999A1|2000-02-02|2005-03-31|Spence Paul A.|Heart valve repair apparatus and methods|
    US6869444B2|2000-05-22|2005-03-22|Shlomo Gabbay|Low invasive implantable cardiac prosthesis and method for helping improve operation of a heart valve|
    DE10046550A1|2000-09-19|2002-03-28|Adiam Life Science Ag|Prosthetic mitral heart valve consists of support housing with base ring and two stanchions|
    GB0125925D0|2001-10-29|2001-12-19|Univ Glasgow|Mitral valve prosthesis|
    US20060195182A1|2002-10-10|2006-08-31|Navia Jose L|Method and apparatus for replacing a mitral valve with a stentless bioprosthetic valve|
    CA2501750A1|2002-10-10|2004-04-22|The Cleveland Clinic Foundation|Method and apparatus for replacing a mitral valve with a stentless bioprosthetic valve having chordae|
    US7404824B1|2002-11-15|2008-07-29|Advanced Cardiovascular Systems, Inc.|Valve aptation assist device|
    US6945996B2|2003-04-18|2005-09-20|Sedransk Kyra L|Replacement mitral valve|
    US7160322B2|2003-08-13|2007-01-09|Shlomo Gabbay|Implantable cardiac prosthesis for mitigating prolapse of a heart valve|
    WO2006113906A1|2005-04-20|2006-10-26|The Cleveland Clinic Foundation|Apparatus and method for replacing a cardiac valve|
    WO2007002320A1|2005-06-27|2007-01-04|The Cleveland Clinic Foundation|Apparatus for placement in the annulus of a tricuspid valve|
    US7455689B2|2005-08-25|2008-11-25|Edwards Lifesciences Corporation|Four-leaflet stented mitral heart valve|
    EP1968492A2|2005-12-15|2008-09-17|Georgia Technology Research Corporation|Systems and methods to control the dimension of a heart valve|
    US20070156229A1|2005-12-30|2007-07-05|Park Jin S|"D"-shape stent for treatment of abdominal aortic aneurysm|
    US8932348B2|2006-05-18|2015-01-13|Edwards Lifesciences Corporation|Device and method for improving heart valve function|
    WO2007139677A2|2006-05-25|2007-12-06|Interventional And Surgical Innovations, Llc|Device for regulating blood flow|
    US7811316B2|2006-05-25|2010-10-12|Deep Vein Medical, Inc.|Device for regulating blood flow|
    US8109993B2|2006-05-25|2012-02-07|Deep Vein Medical, Inc.|Device for regulating blood flow|
    US8403979B2|2007-05-17|2013-03-26|Cook Medical Technologies Llc|Monocuspid prosthetic valve having a partial sinus|
    US8216303B2|2007-11-19|2012-07-10|The Cleveland Clinic Foundation|Apparatus and method for treating a regurgitant heart valve|
    CN102083391B|2008-04-23|2015-02-18|麦德托尼克公司|Stented heart valve devices|
    US8323336B2|2008-04-23|2012-12-04|Medtronic, Inc.|Prosthetic heart valve devices and methods of valve replacement|
    WO2010037141A1|2008-09-29|2010-04-01|Cardiaq Valve Technologies, Inc.|Heart valve|
    US8734502B2|2008-12-17|2014-05-27|Cook Medical Technologies Llc|Tapered stent and flexible prosthesis|
    US20100210899A1|2009-01-21|2010-08-19|Tendyne Medical, Inc.|Method for percutaneous lateral access to the left ventricle for treatment of mitral insufficiency by papillary muscle alignment|
    US10433956B2|2010-02-24|2019-10-08|Medtronic Ventor Technologies Ltd.|Mitral prosthesis and methods for implantation|
    US8579964B2|2010-05-05|2013-11-12|Neovasc Inc.|Transcatheter mitral valve prosthesis|
    JP5848345B2|2010-07-09|2016-01-27|ハイライフ エスエーエス|Transcatheter atrioventricular valve prosthesis|
    US8845717B2|2011-01-28|2014-09-30|Middle Park Medical, Inc.|Coaptation enhancement implant, system, and method|
    RU122876U1|2012-05-22|2012-12-20|Федеральное государственное бюджетное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" Сибирского отделения Российской академии медицинских наук |AORTIC VALVE PROSTHESIS IMPLANTATION SYSTEM|
    US20140031857A1|2012-07-25|2014-01-30|Boston Scientific Scimed, Inc.|Embolic protection filter for transcatheter aortic valve replacement and uses thereof|
    RU2672804C2|2013-01-25|2018-11-19|Медтентиа Интернэшнл Лтд Ой|System for cardiac valve repair|
    CA2910948C|2013-05-20|2020-12-29|Twelve, Inc.|Implantable heart valve devices, mitral valve repair devices and associated systems and methods|
    WO2015017689A1|2013-08-01|2015-02-05|Robert Vidlund|Epicardial anchor devices and methods|
    CN107896484B|2015-02-05|2020-09-08|坦迪尼控股股份有限公司|Expandable epicardial pad and delivery devices and methods therefor|
    EP2918248A1|2014-03-11|2015-09-16|Epygon Sasu|An expandable stent-valve and a delivery device|
    CN108135695A|2015-10-08|2018-06-08|新加坡国立大学|A kind of mitral of native configurations|
    US10940002B2|2017-06-28|2021-03-09|Harmony Development Group, Inc.|Force transducting inflatable implant system including a dual force annular transduction implant|US20090105813A1|2007-10-17|2009-04-23|Sean Chambers|Implantable valve device|
    EP2918248A1|2014-03-11|2015-09-16|Epygon Sasu|An expandable stent-valve and a delivery device|
    EP2918247A1|2014-03-11|2015-09-16|Epygon Sasu|A prosthetic valve and a delivery device|
    FR3021208B1|2014-05-23|2021-03-12|Thomas Modine|MITRAL OR TRICUSPID HEART VALVE PROSTHESIS|
    TW201603851A|2014-07-01|2016-02-01|賽諾菲公司|Drug delivery device|
    WO2016178126A1|2015-05-05|2016-11-10|The Medical Research Infrastructure And Health Services Fund Of The Tel-Aviv Medical Center|Mitral valve implant|
    ES2742204T3|2015-06-04|2020-02-13|Epygon|Atrioventricular valve stent with grip and clamping mechanism of native leaflet|
    EP3100701A1|2015-06-04|2016-12-07|Epygon Sasu|Mitral valve stent with anterior native leaflet grasping and holding mechanism|
    GB2539444A|2015-06-16|2016-12-21|Ucl Business Plc|Prosthetic heart valve|
    WO2017079153A1|2015-11-02|2017-05-11|University Of Maryland, Baltimore|Distal anchor apparatus and methods for mitral valve repair|
    WO2017156133A1|2016-03-08|2017-09-14|Dura Biotech|Heart valve leaflet replacement system and method for same|
    US20170360558A1|2016-06-16|2017-12-21|Jianlu Ma|Method and design for a mitral regurgitation treatment device|
    US10350062B2|2016-07-21|2019-07-16|Edwards Lifesciences Corporation|Replacement heart valve prosthesis|
    US11241307B2|2016-10-13|2022-02-08|Boston Scientific Scimed, Inc.|Replacement heart valve with diaphragm|
    WO2018145249A1|2017-02-07|2018-08-16|上海甲悦医疗器械有限公司|Device for treating regurgitation of tricuspid valve and implantation method therefor|
    WO2018150392A1|2017-02-20|2018-08-23|Epygon|Atrio-ventricular prosthesis with asymmetric flow|
    EP3595587A4|2017-03-13|2020-11-11|Polares Medical Inc.|Device, system, and method for transcatheter treatment of valvular regurgitation|
    US10595994B1|2018-09-20|2020-03-24|Vdyne, Llc|Side-delivered transcatheter heart valve replacement|
    US11071627B2|2018-10-18|2021-07-27|Vdyne, Inc.|Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis|
    US11109969B2|2018-10-22|2021-09-07|Vdyne, Inc.|Guidewire delivery of transcatheter heart valve|
    CN109199640B|2018-10-24|2020-06-12|宁波健世生物科技有限公司|Artificial valve prosthesis|
    US11253359B2|2018-12-20|2022-02-22|Vdyne, Inc.|Proximal tab for side-delivered transcatheter heart valves and methods of delivery|
    US11185409B2|2019-01-26|2021-11-30|Vdyne, Inc.|Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis|
    US11076956B2|2019-03-14|2021-08-03|Vdyne, Inc.|Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis|
    US11173027B2|2019-03-14|2021-11-16|Vdyne, Inc.|Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same|
    AU2020267390A1|2019-05-04|2021-11-11|Vdyne, Inc.|Cinch device and method for deployment of a side-delivered prosthetic heart valve in a native annulus|
    WO2021035032A1|2019-08-20|2021-02-25|Vdyne, Inc.|Delivery and retrieval devices and methods for side-deliverable transcatheter prosthetic valves|
    US11234813B2|2020-01-17|2022-02-01|Vdyne, Inc.|Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery|
    CN111329622B|2020-03-05|2021-06-15|杭州金杭齐医疗科技有限公司|Intervention type artificial heart valve|
    法律状态:
    2018-07-10| B25D| Requested change of name of applicant approved|Owner name: EPYGON (FR) |
    2018-12-04| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-09-08| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-04-20| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-06-01| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/04/2013, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    IT000372A|ITTO20120372A1|2012-04-27|2012-04-27|MONOCUSPIDE CARDIAC VALVE PROSTHESIS|
    ITTO2012A000372|2012-04-27|
    PCT/EP2013/058708|WO2013160439A1|2012-04-27|2013-04-26|Heart valve prosthesis|
    [返回顶部]